Literature DB >> 8562183

Cytotoxic agents with activity in breast cancer patients previously exposed to anthracyclines: current status and future prospects.

M J Piccart1, E Raymond, M Aapro, E A Eisenhauer, E Cvitkovic.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 8562183     DOI： 10.1016/0959-8049(95)00266-l

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN： 0959-8049            Impact factor:   9.162


× No keyword cloud information.
  4 in total

1.  Biweekly vinorelbine and tegafur/uracil in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: GEICAM 2000-02 phase II study.

Authors:  Antonio Antón; Agustí Barnadas; Jesús Florián; Nuria Ribelles; María Lomas; Juan Lao; Ana González-Quintás; Mireia Margelí; Ana Belén Paules; Javier Gayo; Manuel Ramos
Journal:  Clin Transl Oncol       Date:  2011-04       Impact factor: 3.405

2.  Capecitabine and oxaliplatin in combination as first- or second-line therapy for metastatic breast cancer: a Wisconsin Oncology Network trial.

Authors:  U O Njiaju; A J Tevaarwerk; K Kim; J E Chang; R M Hansen; T L Champeny; A M Traynor; S Meadows; L Van Ummersen; K Powers; J A Stewart
Journal:  Cancer Chemother Pharmacol       Date:  2012-12-11       Impact factor: 3.333

3.  A human breast cancer model for the study of telomerase inhibitors based on a new biotinylated-primer extension assay.

Authors:  E Raymond; D Sun; E Izbicka; G Mangold; E Silvas; B Windle; S Sharma; H Soda; R Laurence; K Davidson; D D Von Hoff
Journal:  Br J Cancer       Date:  1999-07       Impact factor: 7.640

4.  Salvage chemotherapy with high-dose leucovorin (LV) and 48-hour continuous infusion (CI) of 5-fluorouracil (5-FU) in combination with conventional doses of cyclophosphamide (CPM) in patients with metastatic breast cancer (MBC) pretreated with anthracycline and taxanes.

Authors:  K Kalbakis; C Kouroussis; S Kakolyris; D Mavroudis; J Souglakos; S Agelaki; L Vamvakas; M Christodoulakis; K Stylianou; V Georgoulias
Journal:  Br J Cancer       Date:  2001-09-14       Impact factor: 7.640
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.